Stock comparison
GILEAD SCIENCES, INC. is 42.1x more valuable than Relay Therapeutics, Inc. by market capitalization ($167.41 B vs $3.98 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
GILD is larger
GILEAD SCIENCES, INC. is 42.1x more valuable than Relay Therapeutics, Inc. by market capitalization ($167.41 B vs $3.98 B).
Market value leader
GILD
GILEAD SCIENCES, INC. is 42.1x more valuable than Relay Therapeutics, Inc. by market capitalization ($167.41 B vs $3.98 B).
Revenue leader
GILD
RLAY: $15.36M vs GILD: $29.44B.
Profit leader
GILD
RLAY: -$276.48M vs GILD: $8.51B.
Margin leader
GILD
RLAY: -1800.6% vs GILD: 28.9% net margin.
| Metric | RLAY | GILD |
|---|---|---|
| Market cap | $3.98 B | $167.41 B |
| US-listed rank | #1611 | #92 |
| Revenue (latest FY) | $15.36M | $29.44B |
| Net income (latest FY) | -$276.48M | $8.51B |
| Net margin | -1800.6% | 28.9% |
| P/E (trailing FY) | - | 19.7x |
| SEC filings | 506 | 968 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
GILEAD SCIENCES, INC. is 42.1x more valuable than Relay Therapeutics, Inc. by market capitalization ($167.41 B vs $3.98 B).
In their latest fiscal years, Relay Therapeutics, Inc. reported $15.36M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Relay Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.